Compare Wix.Com Ltd (WIX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wix.Com Ltd vs Zoetis Inc — how do they compare? Wix.Com Ltd trades at $75.31 (market cap $3.11B), while Zoetis Inc trades at $74.38 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 9.7× Wix.Com Ltd's market cap, and Zoetis Inc pays a 2.9% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Wix.Com Ltd for 62 Days and Zoetis Inc for 70 Days on average.
| WIX | ZTS | |
|---|---|---|
Market Cap | $3.11B | $30.20B |
Volume | 809,286 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $145.54 | $147.53 |
52-Week Low | $40.43 | $69.09 |
Typical Hold Time | 62 Days | 70 Days |
Enterprise Value | $4.19B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WIX trades at $75.06, up 2.86% today, near the consensus price target of $77.00. The stock shows mixed technical signals with a neutral overall rating but bullish moving averages. Revenue growth is strong, reaching $1.99 billion in 2025, though net income turned positive only recently. However, negative shareholder equity and a class action lawsuit filed in September 2026 present significant headwinds. Analyst sentiment remains largely positive with 63% buy ratings, but recent earnings misses add caution.
The outlook is cautiously optimistic given solid revenue expansion and analyst support, but high valuation multiples, litigation overhang, and inconsistent profitability pose risks. Investors should weigh growth potential against financial stability concerns and legal uncertainties before committing capital.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
